Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC - Trial NCT06324058
Access comprehensive clinical trial information for NCT06324058 through Pure Global AI's free database. This phase not specified trial is sponsored by Huashan Hospital and is currently Not yet recruiting. The study focuses on Bladder Cancer. Target enrollment is 190 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Huashan Hospital
Timeline & Enrollment
N/A
Mar 18, 2024
Mar 18, 2026
Primary Outcome
Tumor residual rate
Summary
This trial plans to enroll 190 eligible patients and randomize them into two groups with a
 1:1 ratio, with 95 patients in each group. The experimental group will receive immediate
 cryoablation therapy at the resection site after TUR, while the control group will only
 undergo TUR and receive conventional BCG instillation therapy postoperatively. Both groups of
 subjects will undergo Re-TURBT or cystoscopy 10-12 weeks after surgery to compare the
 tumor-free residual rates and adverse events between the two groups.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06324058
Non-Device Trial